The offering provides necessary capital for late-stage trials and potential NDA submission, but the dilution and insider selling are near-term negatives. Watch for the stock's reaction at open and any further insider transactions. The next major catalyst is CHAPTER-3 topline data in Q3 2026.
Price Chart
Executive Summary
Pharvaris priced a $115M underwritten offering of 3.87M shares at $29.68 per share, representing ~6% dilution. The capital raise funds late-stage HAE/AAE programs, but recent insider selling ($1.8M in 30 days) and dilution create near-term headwinds. The offering closes May 11, 2026.
Key Financial Metrics
Key Facts
- Priced 3,874,664 ordinary shares at $29.68 per share for gross proceeds of ~$115M
- Underwriters have a 30-day option for up to 581,199 additional shares
- Offering expected to close on or about May 11, 2026
- Joint book-running managers: Morgan Stanley, Leerink Partners, Cantor, Wells Fargo Securities
- Proceeds to fund clinical development and potential commercialization of deucrictibant for HAE and AAE-C1INH
- Recent insider selling: 4 transactions totaling $1.8M in the past 30 days
Financial Impact
~6-7% dilution based on ~64M shares outstanding implied by $1.9B market cap at $29.68; gross proceeds of $115M
Risk Factors
- Dilution of ~6-7% reduces EPS and ownership for existing shareholders
- Insider selling ahead of offering may signal lack of confidence
- Clinical trial risks for deucrictibant (HAE/AAE programs)
- Regulatory approval uncertainty for NDA submission planned in H1 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290920 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access